Data have linked propoxyphene and fatal overdoses. In response to these data, the Food and Drug Administration (FDA) has taken actions to reduce the risk of overdose in patients using pain medications that contain propoxyphene (eg, Darvon and Darvocet). The FDA now requires manufacturers of propoxyphene-containing products to (1) strengthen the label, including the boxed warning, emphasizing the potential for overdose when using these products, and (2) to provide a medication guide to patients, stressing the importance of using the drugs as directed. For more information, go to www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.htm.

Astudy funded by the Agency for Health-care Research and Quality examines the use of radiofrequency catheter ablation to treat atrial fibrillation. This study shows that although the procedure provides benefits in maintaining normal heart rhythm over short periods (up to 1 year), little evidence indicates whether the procedure reduces the chance that patients will experience atrial fibrillation over the long...

You do not currently have access to this content.